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Until the recent advent of monoclonal antibodies (mAb) ~ specific for human 
T cells, the most widely used marker for human peripheral T cells and thymocytes 
was their ability to bind sheep red blood cells (SRBC) (1-4). Early studies using 
polyvalent anti-T cell sera suggested that the interaction resulting in E rosettes 
is  mediated  by  specific  receptors  on  the  human  T  cells  (5),  a  notion  fully 
confirmed by the discovery that mAb against the T cell surface molecule carrying 
T 1 1 and related markers block rosette formation (6-9). Nevertheless, E rosetting 
remained a curious, if useful, phenomenon until a functional involvement of the 
E receptor in  T  cell activation  was suggested by a  number of findings:  First,  it 
was shown  that  the  rosetting  procedure  rendered  T  cells  reactive  to  growth 
factor(s) (10).  More recently, anti-T11  mAb were reported  to either  inhibit  T 
cell  activation  (1 1-15)  and  T  cell-mediated  cytolysis (12,  13),  or,  if certain 
combinations  of mAb  were  used,  to  lead  to  polyclonal  T  cell  activation  (14). 
Accordingly,  a  "physiological  ligand"  of the  E  receptor  with  a  role  in  T  cell 
activation  was  postulated  (11-13,  16),  which  could  be  envisaged  as  either  a 
soluble mediator or a cell surface structure on cells with which T  cells interact. 
We have pursued  the latter hypothesis and have developed an experimental 
approach  based  on  the  following assumption:  The  binding  of RBC  to  the  E 
receptor is not due to fortuitous crossreactivity with the unknown physiological 
ligand. Since human  T  cells also bind autologous RBC (17), the target for T1 1 
on RBC may be the physiological ligand itself; this ligand may be expressed on 
other cell types as well, where it is not as easily visualized by rosetting but may 
play its role in cellular interactions. 
In  the  present  report,  the  identification,  isolation,  and  partial  biochemical 
characterization of the target structure for T 1 1 (T 1 1TS) is described. In contrast 
to earlier  attempts  to  define  this  molecule by conventional  biochemistry (18- 
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20), we have affinity purified T 11TS with an mAb to SRBC that abrogates their 
binding to human and sheep T  lymphocytes. 
Materials and Methods 
Preparation of Cells.  Freshly drawn human blood from healthy individuals  was centri- 
fuged in balanced salt solution (BSS) with heparin. The buffy coat cells were centrifuged 
over FicolI-Paque (Pharmacia, Inc., Uppsala, Sweden) to prepare peripheral blood lym- 
phocytes (PBL).  Human RBC (HuRBC) and PBL were washed three times in BSS before 
use.  Fresh SRBC were washed twice in BSS with heparin. The buffy coat was collected, 
spun down, and resuspended in 90% Percoll (Pharmacia, Inc.) in BSS. 70 and 50% Percoll 
suspensions and BSS were layered on top, and, after 20 min centrifugation with 180 g at 
room temperature,  white  blood cells  were collected from the  interphase  between  the 
BSS/50% Percoll and 50%/70% Percoll. Sheep white blood cells (SWBC) were stimulated 
with 2 ttg concanavalin A (Con A) (Pharmacia, Inc.) per milliliter  RPMI  1640 with 5% 
fetal  calf serum  (FCS),  5  ×  10 -5 M  2-mercaptoetbanol,  nonessential amino acids,  and 
antibiotics.  After  1 wk,  Con  A  was  washed  out and  the  cells  were  recultured  in  the 
presence of 5 U/ml of recombinant human interleukin 2 (IL-2), the kind gift of Drs. Fiers 
and Devos, Biogent, Ghent, Belgium. Prolonged culture was performed by culturing with 
IL-2 and alternating the presence and absence of Con A on a weekly schedule.  Before 
use, these T  cell blasts  were washed again in BSS with  20 mg/ml a-methyl mannoside to 
remove Con A. 
Assay  for E Rosettes.  SRBC and HuRBC were treated with neuraminidase (Testneura- 
minidase; Behringwerke AG, Marburg,  FRG) diluted  1:50 in  BSS for 30 min at  37°C, 
washed, and adjusted to 10S/ml and 2.5 ×  107/ml, respectively in BSS with 5% FCS (BSS/ 
FCS).  Human PBL were either  left untreated (for sheep E rosettes),  or neuraminidase 
treated (for autologous rosettes),  washed, and adjusted to 8 x  106/ml in BSS/FCS. Sheep 
T  cell blasts  were also treated with neuraminidase and adjusted to 8 ×  106 BSS/FCS. 50 
ttl of lymphocytes were mixed with 50 IA of RBC and 50 tA of BSS/FCS. For rosettes of 
human PBL with SRBC, the mixture was left for 10 min at room temperature, centrifuged 
for 2 min at 200 g, and left for another 30 min at room temperature. Autologous human 
and sheep rosettes were prepared  by incubating the cell  mixture for 20 min at  37°C, 
centrifuging for 5  min at  200 g, and leaving the pelleted  cells  for 60 min on ice.  All 
rosettes were microscopically enumerated after gently resuspending the cells and staining 
with crystal violet.  400 nucleated cells were examined per test,  and nucleated cells with 
three or more bound RBC were scored as rosettes. 
E Rosette Inhibition Assay.  mAb to SRBC were assayed by preincubating 50 #1 of SRBC 
with 50 ~1 of antibody preparations for 30 min at room temperature,  followed by the 
addition of lymphocytes and the rosetting procedure as described above. Anti-T11 mAb 
(Coulter Immunology, Hialeah,  FL) or partially purified T1 ITS were assayed by prein- 
cubating  50  tLl  of  these  preparations  with  50  ttl  lymphocytes for  30  min  at  room 
temperature before proceeding with the assay. To determine whether lymphocytes or red 
cells  are  the  target  of inhibition,  each  partner  was  preincubated  with  the  relevant 
preparation for 30 min at room temperature,  washed twice with BSS/FCS followed by 
the addition of the untreated partner, and the assay performed as described above. 
Isolation ofmAb L180/1.  Supernatants from a total of 86 SRBC-specific  hybridomas, 
produced in two separate fusions from SRBC primed and boosted BALB/c mice with the 
nonsecreting myeloma X63-Ag 8.653, were screened for inhibition of rosettes between 
human PBL and SRBC. These hybridomas were kindly provided by M.  Lohoff at this 
institute. One culture, termed L180, scored positive.  It was subcloned, and antibody was 
purified from culture supernatant and ascites  by ammonium sulphate precipitation and 
salt-gradient elution  from DEAE-Affigel Blue  (Bio-Rad Laboratories,  Richmond, CA). 
The antibody L180/1  is of the  IgG class and binds to protein A.  Fab fragments were 
prepared by digestion with insolubilized papain (Sigma GmbH, Taufkirchen, FRG) and 
examined for purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE).  For controls,  normal  mouse IgG (NMIgG) was  purified  from serum.  Protein 
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Preparation of Surface-labeled  Cell Extracts.  100 ~1 of packed SRBC were washed three 
times in phosphate-buffered saline  (PBS) containing 5 X 10  -6 M KI and resuspended in 
0.9 ml of this buffer. 2.5 U of lactoperoxidase (Sigma GmbH), 1 mCi of ~5I as NaI, and 
10 #l of 0.3% H~O~ were added. 1 U lactoperoxidase and 10 #1 of 0.3% H~O~ were added 
again, twice, at 4-min intervals. The reaction was stopped after another 8 rain by washing 
the  cells  three  times  in  PBS  containing  5  x  10  -3  M  KI.  For  labeling  of cell  surface 
carbohydrates, 5 x  108 SRBC were treated with 0.25 U neuraminidase and 25 U galactose 
oxidase (Sigma  GmbH) in 5 ml BSS for 45 rain at 37°C, washed once in cold PBS, and 
resuspended in 2 ml cold PBS containing 30 mCi tritiated BH4- (NEN, Dreieich, FRG). 
After 30 min on ice the cells were washed three times in PBS. Surface-labeled cells were 
lysed in 2 ml PBS containing 0.5% Nonidet P-40 (NP-40) (Roth, Karlsruhe, FRG), 0.02% 
deoxycholate (Sigma GmbH), and 70 #g/ml aprotinin (Trasylol; Bayer, Leverkusen, FRG). 
After 15 rain on ice the lysate  was spun for 30 rain at 20,000 rpm, and the pellet was 
discarded. 
Radioimmunoprecipitation  (RIP).  Purified  mAb  L180/1  or  NMIgG were  covalently 
coupled to agarose beads according to the manufacturer's suggested procedure (Affigel 
10; Bio-Rad Laboratories). ~3.5 mg IgG bound per milliliter  of gel. Before radioimmu- 
noprecipitation (RIP), the beads were washed three times in lysis buffer.  100-200 #! of 
radiolabeled lysate were kept with 50 #i of NMIgG-coupled beads for 30 min on ice. The 
supernatant was collected by centrifugation, and 50 #1 L18011 or NMIgG-coupled beads 
were added.  After 60  min  on ice,  the  beads  were  washed  three  times in  lysis buffer 
containing 0.5 M KCI and three times in lysis buffer. 
Large-Scale  Enrichment of TIlTS.  100  ml  of PBS-washed,  packed SRBC were  lysed 
with an  equal  volume of PBS  containing  1%  NP-40,  0.04%  deoxycholate, and  70  #g 
aprotinin. After 30 min on ice, the lysate  was centrifuged for 30 min at 20,000 rpm in 
the cold. The supernatant was passed dropwise over 1 ml of mAb L 180/1-coupled Affigel 
10.  The immunosorbent column was washed with 50 ml lysis buffer containing 0.5  M 
KCI and 50 ml lysis buffer without KCI. The gel was removed from the column, residual 
buffer was aspirated,  and  the  bound  material  was eluted  overnight with  2  ml  3.5  M 
NH4SCN, pH 8.0 containing 0.2% NP-40. The eluate was passed over a Sephadex G-25 
column equilibrated  with  0.1%  NP-40 in  PBS.  Two or three  1-ml fractions that were 
positive  in  the  Bio-Rad protein assay  were collected.  For studies on the interaction of 
affinity-enriched material with viable cells, the gel was washed with PBS before salt elution 
and detergent was omitted during the following steps.  Protein content was determined 
using the Bio-Rad protein assay. 
Crude SRBC Membranes.  50 #1 of packed SRBC were lysed with 1 ml H20. Membranes 
were pelleted and washed three times in 0.2% NaCi by centrifugation at 20,000 rpm for 
5 min. 
SDS-PAGE and Autoradiography.  Samples were boiled in Laemmli sample buffer (21) 
with  or  without  2-mercaptoethanol and  run  on  SDS  slab  gels  containing  10  or  12% 
acrylamide.  ~4C-labeled  markers  were:  cytochrome c  (12  kilodaltons  [kD]),  carbonic 
anhydrase (30 kD), ovalbumin (45 kD),  bovine serum albumin (BSA) (66 kD), phospho- 
rylase b (92  kD) (all from Amersham Buchler, Braunschweig, FRG). Unlabeled markers 
were: lysozyme (14.3 kD), trypsinogen (24 kD), ovalbumin (45 kD), BSA (66 kD) (Sigma 
GmbH). Gels  were fixed, stained with Coomassie Blue,  and dried.  Gels  containing SH- 
labeled  material  were  fluorographed using dimethyl sulfoxide/PPO.  Autoradiography 
was performed with Cronex 2 x-ray film  (DuPont Co., Wilmington, DE) preexposed to 
light,  using enhancing screens. 
Indirect Immunofluorescence  and Flow Cytometry.  2.5 x  l0  s human PBL were preincu- 
bated for 30 min at room temperature with either  100 ~1 PBS or PBS containing 1 #g 
protein eluted from the L 180/1 affinity column. The cells were washed once and treated 
with 4/zg NMIgG, anti-T11  mAb diluted  1:100, or anti-T3 mAb (OKT3; Ortho Diag- 
nostic Systems,  Inc., Raritan, N  J) diluted  1:50, in 0.1  ml PBS containing 0.1% BSA and 
0.02% sodium azide (PBS/BSA/azide). After 30 rain on ice, the PBL were washed in this 
buffer, stained with goat anti-mouse, fluorescein isothiocyanate (FITC)-coupled antibodies 
(Coulter Diagnostics,  Hialeah, FL) diluted 1:50 for 30 min on ice, and washed three times HI]NIG  893 
in  PBS/BSA/azide.  Analysis  was  performed  on  an  Epics  V  flow  cytometer (Coulter 
Electronics, Inc., Hialeah, FL), using a forward angle light scatter gate for lymphocytes 
and collecting integrated green fluorescence signals from a logarithmic amplifier. 
Results 
Inhibition  of Heterologous and Autologous E Rosette Formation by Anti-T11  and 
mAb L180/1.  The culture  supernatants  from a  total  of 86  SRBC-specific hy- 
bridomas from two independent fusions were screened for their ability to inhibit 
rosette formation between human T  cells and SRBC. One positive culture (L 180) 
was  identified, subcloned,  and  the antibody purified from culture supernatant 
and ascitic fluid.  Fab  fragments  were prepared  to eliminate  hemagglutination 
and tested again for rosette inhibition. 
As shown in Fig.  1 A, nanogram amounts of L 180/1  Fab fragments completely 
abrogated the formation of rosettes between human PBL and SRBC. Since mAb 
L180/1  does not bind to HuRBC (data not shown), it was expected that autolo- 
gous human rosettes were not affected by L180/1  Fab (Fig.  1B). On the other 
hand, anti-T 11, which is known to block binding of SRBC to human T  cells (6- 
9) (Fig.  1 A),  also blocked autologous human  rosette formation (Fig.  1 B),  sug- 
gesting that the same E receptor binds SRBC and HuRBC. The absence of the 
epitope recognized by L180/1  from HuRBC could either mean that the target 
structure  recognized  by  the  human  E  receptor  on  SRBC  and  HuRBC  are 
unrelated,  or  that  there  is  antigenic  variation  of the  same  molecule between 
species, as is commonly found. 
If, as hypothesized, the putative  target structure for the E  receptor is a  cell 
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FIGURE  1.  Inhibition of autologous and xenogeneic E rosette formation by anti-T cell and 
anti-erythrocyte mAb. NMIgG (O), mAb to TI 1 (m),  and Fab ofmAb L180/1 (4,) were tested 
for blocking of E rosettes as described in Materials and Methods. In the absence of antibody, 
the fraction of rosette-forming cells was: 62% (A), 24% (B), 9.6% (C). 894  TARGET  STRUCTURE  FOR  THE  E  RECEPTOR 
FrcuR~  2.  Autologous rosette formed between sheep T  cell blast and SRBC. 
interaction  molecule, it must be functioning  in an autoiogous situation  such as 
in  the  binding  of human  T  cells  to  human  erythrocytes.  Since,  as  discussed 
above,  mAb  L180/!  detects  the  putative  ligand  of T11  on  sheep  but not  on 
human  RBC,  we  have  devised  a  protocol  for  the  formation  of sheep-sheep 
rosettes.  Although  freshly  isolated  SWBC  do  not  form  stable  autologous  E 
rosettes, ~ 10% of SWBC activated by Con A and propagated in human recom- 
binant IL-2 bound numerous SRBC to form stable rosettes (Fig. 2). This rosette 
formation  was  completely inhibited  by L180/1  Fab (Fig.  1C),  suggesting  that 
sheep  T  cell  blasts  have  a  receptor  for autologous  RBC  that  binds  the  same 
target structure also recognized by the human T11  molecule. The mAb to T11 
that was used neither bound to sheep T  cell blasts (data not shown) nor inhibited 
sheep  autologous  rosettes  (Fig.  2C).  In  summary,  it  appears  that  analogous 
receptor-ligand  systems exist in man and sheep, and that  the mAb to T11  and 
mAb L180/!  recognize species-specific determinants  on the E  receptor and its 
target, respectively. 
Isolatin of TI 1TSfrom SRBC.  SRBC were either surface iodinated or surface 
labeled  by  treatment  with  neuraminidase  plus  galactose  oxidase  followed  by 
reduction with tritiated borohydride. Immunoprecipitates from detergent lysates 
were analyzed by SDS-PAGE and autoradiography.  As can be seen in Fig. 3A, a 
band with an apparent molecular weight of ~42,000 was precipitated from ~z5I- 
labeled extracts by mAb L180/1  coupled to agarose beads under both reducing 
and  nonreducing  conditions.  The  additional  band  of higher  molecular  weight 
was,  in all experiments  where it was found in  L180/1  immunoprecipates,  also 
present  in  control precipitates.  It  is therefore regarded  as nonspecific.  Immu- 
noprecipitation of 3H-labeled glycosylated membrane molecules revealed a single 
band of slightly smaller apparent molecular weight than observed with iodinated 
extracts.  Note that  this  band  does not comigrate  with  the bulk of the  labeled HClN1G  895 
FIGURE  3.  SDS-PAGEofsurface-labeledSRBCextractsradioimmunoprecipitatedwithmAb 
L180/1. (A) 2~sI-labeled, 10% acrylamide; (B) 3H-labeled, 10% acrylamide reduced; (C) ~sI- 
labeled, 12% acrylamide reduced. Neuraminidase (N'ase) treatment of the lysate (C) was 
performed for 30 min at 37 °C with 1:50 dilution of Tesmeuraminidase. 
material  (Fig.  3B). The difference in  molecular weight between iodinated and 
"~H-labeled  material  is  accounted  for  by the  removal  of sialic  acid  during  the 
labeling procedure used for the latter,  since the same shift in molecular weight 
was observed if 12~I-labeled  extracts  were neuraminidase  treated  before immu- 
noprecipitation (Fig. 3 C). The apparent glycoprotein nature of T 11TS has been 
further  substantiated  by  trypsin  and  endoglycosidase  degradation  (data  not 
shown). 
The ready availability of the starting  material also permitted large-scale puri- 
fication of T 11TS.  As an  initial step, a  detergent  lysate prepared from  100 ml 
packed SRBC was passed over insolubilized mAb L180/1  and eluted with high 
salt. As can be seen in  Fig.  4C, T11TS is a  major, although  not the only band 
visible upon  Coomassie  Blue staining  of the eluate  in  SDS-PAGE.  Subsequent 
radiolabeling  of this  affinity-enriched  material  and  immunoprecipitation  (data 
not shown) confirmed that the band indicated by arrow in Fig. 4 is the material 
precipitated  by mAb  L180/1  as described above. To determine  whether  mAb 
L180/1  precipitates a  major protein of the red ceil membrane,  a  crude SRBC 
membrane preparation (Fig. 4, A and B) and total detergent lysate (Fig. 4, D and 
E) were run in parallel.  It appears that T11TS is only a minor component of the 
red cell membrane as detected by this method.  T11TS can be further purified 
by adsorption  to  Con  A-Sepharose  (not  shown),  and  our  current  efforts are 
directed towards obtaining enough homogeneous material for microsequencing. 
Binding of PartiaUy Purified Tl lTS to the E  Receptor of Human  T Cells.  Initial 
experiments showed that after elution of detergent-solubilized T11 TS from the 
L180/1  affinity column  with  high  salt and  transfer  into  PBS via salt-exchange 
chromatography,  the yield of T11TS  was greatly enhanced  if the presence of 
detergent  was maintained.  However, enough material  for detection by protein 
stains  in  SDS-PAGE  was  recovered  if the  high  salt  eluate  was  transferred  to 
detergent-free  PBS,  permitting  investigation  of the  interaction  between  the 
affinity-enriched  material  and  the  E  receptor  on  viable  cells.  Two  types  of 
experiments  were  performed  with  such  preparations.  First,  we  investigated 
whether partially purified T11TS blocks formation of rosettes between human 896  TARGET  STRUCTURE  FOR  THE  E  RECEPTOR 
FIGURE 4.  Large-scale affinity enrichment of T1 ITS.  (A,  B)  1:10  and  1:100  dilutions of 
crude  SRBC  membranes; (C)  eluate  from  L180/1  affinity column; (D,  E)  1:I00  and  1:10 
dilutions of detergent lysate applied to affinity column. SDS-PAGE (12% acrylamide) was run 
under reducing conditions and stained with Coomassie Blue. 
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FICURE  5.  Inhibition of E rosette formation by affinity-enriched T11TS. Human PBL were 
preincubated  with  the  eluate  from  the affinity column  before  addition  of neuraminidase- 
treated SRBC. In the absence of TI ITS, 58% of PBL formed rosettes. 
PBL and SRBC (Fig. 5). Complete inhibition was indeed observed when 500 ng 
of protein was added to the assay system. To assess whether the observed effect 
was caused by the putative ligand of the E receptor or by antibody leaking from HUNIG 
TABLE l 
Effect of Preincubation of PBL or SRBC with mAb L 180/1, anti-T11, 
or Partially Purified T11TS on E Rosette Formation 
Percent inhibition of E rosettes after 
pretreatment of: 
Human PBL  SRBC 
Anti-T 11  95  0 
Fab L180/1  0  100 
TILTS  91  18 
PBL or SRBC were preincubated  for 30 min with mAb to T11  (h300 
final), 2 ug Fab of mAb L180/1, or 2 ug of partially purified  T11TS, 
washed, and tested for rosette formation.  66% of nucleated cells formed 
rosettes in untreated controls. 
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FIGURE 6.  Interference of partially purified T11TS with the binding of anti-T11 to human 
PBL. PBL were preincubated  with affinity-enriched T1 ITS, washed, and stained with anti- 
T 11 and anti-T3, followed by FITC-coupled goat anti-mouse Ig as described in Materials and 
Methods. NMIgG was included as a negative control but, for reasons of clarity, is not shown. 
the  immunosorbent  column,  PBL or SRBC  were separately preincubated  with 
either anti-T11  mAb,  Fab L180/1,  or partially purified T11TS,  then  washed, 
mixed  with  the  untreated  partner,  and  examined  for  rosettes  (Table  I).  As 
expected, T1 1 mAB and partially purified T1 ITS blocked rosette formation if 
the  PBL  were  preincubated,  whereas  mAB  L180/1  was  only  effective  after 
pretreatment of red cells. It appears, therefore, that a protein was present in the 
column eluate that was capable of competing with the binding site for red cells 
on human T  cells. 
More  direct  evidence  for  the  binding  of partially  purified  T11TS  to  the  E 
receptor is presented in Fig. 6.  Human  PBL were preincubated with the eluate 
from the  affinity column  or with control  buffer,  washed,  treated  with  mAb to 
T11  or to T3, stained with FITC-conjugated second antibody, and analyzed by 
flow cytometry. Pretreatment with the preparation believed to contain  T1 1TS 
resulted in a  marked reduction  of staining with the anti-T11  mAb, but had no 
effect on  staining  with  anti-T3  mAb.  This  indicates  a  specific blocking of the 
binding site recognized by anti-T 11 and thus confirms the presence of E receptor 
binding material in the affinity-enriched preparation. 898  TARGET  STRUCTURE  FOR  THE  E  RECEPTOR 
Discussion 
The  results  presented  here  show  that  an  mAb  to  SRBC,  termed  L180/1, 
completely inhibits  rosette formation between human  or sheep T  lymphocytes 
and SRBC. In addition, the molecule recognized by this mAb, a minor glycopro- 
tein of the SRBC membrane with an apparent molecular weight of ~42,000 (42 
K), also inhibited rosette formation and the binding of anti-T11  mAb to the E 
receptor on  human  T  cells.  Since these findings  appear  to indicate  that  mAb 
L180/1  detects the cell surface molecule recognized by the E receptor, we have 
given this glycoprotein the preliminary name T11 target structure, or T11TS. 
This is not the first report claiming the identification of the SRBC membrane 
molecule involved in rosette formation, although  blocking of the E receptor as 
detected by reduced binding of mAb to T11 (Fig. 6) has, to our knowledge, not 
been described.  Kitao et al.  (18) described a  sialoglycopeptide of 10 K  mol wt 
released  from  SRBC  by  trypsin,  which  blocked  the  formation  of E  rosettes; 
Fletcher  et al.  (19)  demonstrated  rosette  inhibition  with  glycoproteins of 37, 
26.5,  and  9  K  mol  wt  that  were  isolated  by biochemical  means  from  SRBC 
membranes.  In contrast,  Gfirtler (20) detected rosette-inhibiting  activity in the 
glycolipid fraction of SRBC membranes.  The relationship between these prepa- 
rations and the molecule described here is unclear at present,  but it should be 
noted that in these reports the amount of glycoprotein or glycolipid required to 
block rosette formation was several hundred-fold  higher than  is reported here 
for the partially affinity-purified material. Thus, the active component may have 
comprised only a  small minority of the glycoprotein or glycolipid preparations 
isolated biochemically. Indeed, the results in Figs. 3 and 4 show that the molecule 
recognized by mAb L180/1  is not one of the major glycoproteins of the well- 
studied  red  cell  membrane  (22),  a  finding  corroborated  by the  expression  of 
T11TS  on  white  blood cells also (H/inig,  manuscript  in preparation).  We are 
presently attempting to purify enough material for microsequencing, so that the 
identity of T11TS will hopefully be soon resolved. 
The nature of the interaction between the E receptor and its target structure 
remains unclear, although  several laboratories have presented evidence for the 
recognition of sugar moieties on the red cell membrane.  Boldt and Armstrong 
(23) demonstrated rosette inhibition  by several glycoproteins rich in sialic acid, 
galactose, N-acetyl glucosamine, and mannose, although at concentrations several 
orders of magnitude higher than were required for blocking in our experiments. 
Moreover, Fletcher et al. (19) reported that the glycoproteins which they isolated 
lost their activity in the rosette inhibition assay after enzymatic desialylation, an 
apparent  contradiction  to the enhanced rosette-forming capacity of neuramini- 
dase-treated  SRBC.  We have  confirmed  this  finding  to  some extent  with  the 
glycoprotein studied here (data not shown), but the poor solubility of T11TS in 
the absence of detergents suggests that the reduction in inhibitory activity after 
desialylation  may  not  be  due  to  destruction  of the  site  recognized  by the  E 
receptor but rather  to a  further  loss of solubility in aqueous buffers.  It should 
be added  that  neuraminidase  treatment  of SRBC or iodinated  lysates did  not 
impair the binding of mAb L180/1  as determined by radioimmunoprecipitation 
(Fig. 3 C) and quantitative flow cytometry (data not shown), indicating that sialic 
acid residues are not directly involved in the antigenic determinant  recognized HIJNIG  899 
by this mAb. Nevertheless, it cannot be distinguished  at present whether mAb 
L180/1, much less the E receptor, recognize the protein or the sugar moiety of 
TllTS.  Experiments  addressing  this  question  are  under  way.  Quite  clearly, 
however, the complete inhibition of rosette formation by nanogram amounts of 
Fab fragments of an  mAb specific for only one minor glycoprotein of the red 
cell  membrane  demonstrates  that  the  interaction  of the  E  receptor  with  its 
complementary structure is highly selective. 
The expression of T11TS on white blood cells (Hiinig,  manuscript in prepa- 
ration) points to the possible biological significance of this interaction; the present 
demonstration of autologous rosettes in the sheep system that appear to use the 
same molecule on SRBC as that recognized by human T  lymphocytes (Fig.  1), is 
intriguing  in  this  respect.  The  E  receptor as defined  by anti-T! 1 and  related 
mAb is widely distributed among primates (24), and the present results suggest 
that an analogous system also exists in more distantly related mammals.  In this 
context,  it is of interest that anti-T11  mAb blocked both heterologous rosettes 
between human T  cells and SRBC, and autologous human rosettes (Fig.  1). This 
suggests that  the  E  receptor target  system is  highly conserved and  that  SRBC 
rosetteing is more than an immunological curiosity. One may speculate that red 
cell rosetting  involves the  interaction  of complementary cell  interaction  mole- 
cules, a  notion fully consistent with published experiments on the regulation of 
T  cell activation via the E receptor (10-16). 
Summary 
A monoclonai antibody (mAb) to sheep red blood cells (SRBC), termed L180/ 
1,  is  described  that  completely  blocks  rosette  formation  between  SRBC  and 
human  or sheep T  lymphocytes.  L180/1  precipitated  a  minor  glycoprotein of 
about ~42,000 mol wt from surface-labeled SRBC. This glycoprotein was par- 
tially affinity purified and  found to block E  rosette formation and  to compete 
with anti-T11  mAb for the E receptor. The molecule detected by mAb L180/1 
thus appears to be recognized by the E receptor and was given the preliminary 
name, T11 target structure (T11TS). Since the mAb to sheep T11TS blocks the 
binding of SRBC to both human and sheep T  cells, and mAb to T11 blocks the 
binding  of red  cells  from  human  and  sheep  to  the  human  E  receptor,  we 
concluded that analogous receptor-ligand (T 11-T 11TS) systems exist in man and 
sheep that are crossreactive over the species barrier.  The possibility is discussed 
that  the  E  receptor,  which  is  known  to be  involved  in  T  cell  activation,  and 
T 11TS function as complementary cell interaction molecules in T  cell responses. 
I thank Rita Mitnacht  for excellent technical  assistance, M. Lohoff for his collection  of 
SRBC-specific hybridomas, Drs. Fiefs and Devos for their gift of recombinant human IL- 
2, Drs. A. Schimpl and E. Wecker for helpful discussions, and Ch. Stoppe and B. Jordan 
for typing this manuscript. 
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